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Syndromic management of STIs and the threat of untreatable Mycoplasma genitalium
Takashi Deguchi 1 describes issues in syndromic management of sexually transmitted infections (STIs) and in particular treatment of Mycoplasma genitalium, which shows increasing drug resistance, especially in the Asia-Pacific region, and which might become the first untreatable STI. 2 Widespread syndromic use of azithromycin has increased macrolide resistance in several bacterial STIs, and the evidence that macrolide resistance is less likely to develop with an "extended" azithromycin regimen as suggested by Deguchi 1 is not strong. 3 We clearly need to replace syndromic approaches with therapy determined by identification of the causative organism, which will be facilitated by point-of-care tests, which also need to determine drug-resistance profiles for STIs such as M genitalium and Neisseria gonorrhoeae. 4 There is, however, an urgent need to establish guidelines for testing, to avoid widespread asymptomatic screening for M genitalium. Although M genitalium has similar prevalence to Chlamydia trachomatis, 2 screening cannot currently be recommended. Uncertainty in the natural history of M genitalium causes large uncertainty in the potential benefits of screening, 5,6 and there is concern about selection for antimicrobial resistance and drug toxicity. 7 Treatment of M genitalium is increasingly challenging with resistant cases requiring costly drugs, which often have limited availability and are associated with rare, but serious, side-effects. 1, 2 Until regimens that are more effective and tolerable become available, we recommend sexual health services to avoid unnecessarily identifying asymptomatic infections, due to the consequent imperative to treat. The only patients in whom testing for M genitalium is clearly indicated are those with symptoms (urethritis, cervicitis, pelvic inflammatory disease 7 ), and current partners of index patients infected with M genitalium (even if asymptomatic), to prevent potential reinfection. Multiplex tests 8 detecting M genitalium should not be routinely used for patients seeking sexual health care without disease because such an approach would create a de-facto screening programme. However, more information is needed to better understand M genitalium's natural history, and unlinked anonymous monitoring of samples from asymptomatic patients tested for other STIs would provide valuable information that could inform treatment guidelines, including rates of M genitalium co-infection with C trachomatis and N gonorrhoeae. 6 Treatment of C trachomatis and N gonorrhoeae with azithromycin will select for resistance in patients coinfected with M genitalium and this use needs to be reviewed.
To manage M genitalium effectively, testing should always include the antimicrobial resistance profile: antimicrobial resistance is the primary cause of treatment failure with azithromycin and quinolones. 3 Treatment should always be followed by test of cure: some treatment failures have been observed to have a reduced bacterial load and mild or unnoticed symptoms or signs, creating an opportunity for propagation of resistance. www 
Use of prevalence data to study sepsis incidence and mortality in intensive care units
Flavia Machado and colleagues 1 used a cross-sectional sampling design and a conversion formula to estimate the incidence of sepsis in Brazilian intensive care units (ICUs) and to examine factors associated with mortality. We would like to point out several important aspects regarding the conversion from prevalence to incidence and proportions, and how they can be addressed. Previous studies have shown that conversion formulas can be seriously flawed. Haore and colleagues 2 reported that the observed cumulative incidence of hospital-acquired infections was up to three-times higher than the calculated cumulative incidence from the prevalence data. Several conversion formulas can be used, the most commonly known for studies of health-care-associated infections is that of Rhame and Sudderth. 3 This formula and the one used by Machado and colleagues require the assumption of the socalled steady state-ie, the number of patients entering and leaving the hospital or ward is balanced at any period. This assumption should be confirmed before reporting incidence and proportions from prevalence studies, and various graphical and formal tests are available to check this assumption. 4 When steady state does not hold, mathematical extensions can be used, such as the plug-in estimator suggested by Mandel and Fluss. 5 Cross-sectional studies are biased toward patients who have long lengths of hospital stay. Under steady state, a patient who stays in the ICU for 10 days has twice the chance of being sampled compared with a patient who stays for 5 days. Thus, long-stay patients with more intrinsic risk factors and higher risk of mortality are over-represented than in short-stay patients. This bias directly affects the evaluation of risk factors for mortality, and hence regression models on prevalence data cannot be used to infer patients' risk factors without addressing selection bias of the design. A possible way to correct for the length bias in regression models is to over-weigh patients with short stay, and under-weigh patients with long stay. Regression approaches that do not take the cross-sectional design into account might result in invalid estimates.
Studies such as the one by Machado and colleagues 1 are extremely important, but the analysis should be done with use of appropriate statistical methods. Such methods yield valid estimates without the need of collecting more data. We would like to encourage future cross-sectional studies to take steady state and length of stay into account when estimating incidences and using regression models.
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